rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Wave Life Sciences, Inc.

WVE · Nasdaq

Health CareBiotechnologyNot moving yetGLP-1Synthetic Biology / TechBio

WVE stood above a rising 150-day average in 16 of the last 52 weekly readings, and has been out of that trend for the last 30 weeks. It is 42.6% below that average now. Biotechnology: 18% of its 561 stocks in an uptrend (−14 points in four weeks); Health Care: 28% (−9 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 30
Industry in uptrend
18% -14 in 4 wk
Insider buys, 12 months
$137.2M
Insider sales, 12 months
$17.2M
Officials’ trades on record
0
Institutions holding
228 (+10)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 16 of 52 weeks.

21 Apr – 20 Oct
18%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$104.8MNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months5
Sale orders, 12 months20
Buyers · sellers2 · 11
WhoDidSharesTraded
Adrian RawcliffeDirectorsold12,700at $5.2912 Aug 2026filed 13 Aug 2026
Aik Na TanDirectorsold432at $6.0111 Aug 2026filed 13 Aug 2026
Ken TakanashiDirectorsold3,864at $6.0111 Aug 2026filed 13 Aug 2026
Heidi L. WagnerDirectorsold7,000at $6.0111 Aug 2026filed 13 Aug 2026
Ra Capital Management, L.p.Director, 10% ownerbought971,091at $6.5030 Mar 2026filed 30 Mar 2026
Ra Capital Management, L.p.Director, 10% ownerbought2,495,623at $6.4327 Mar 2026filed 30 Mar 2026
Ra Capital Management, L.p.Director, 10% ownerbought4,954,558at $6.0626 Mar 2026filed 30 Mar 2026
Ra Capital Management, L.p.Director, 10% ownerbought351,224at $6.3826 Mar 2026filed 30 Mar 2026
Chris FrancisOfficersold17,900at $15.0926 Feb 2026filed 27 Feb 2026
Chris FrancisOfficersold15,294at $15.0026 Feb 2026filed 27 Feb 2026
Chandra VargeeseOfficersold3,228at $13.459 Feb 2026filed 11 Feb 2026
Chris FrancisOfficersold1,883at $13.459 Feb 2026filed 11 Feb 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders228+10 on the quarter
New · exited50 · 41
Reported value$1.1B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
RA CAPITAL MANAGEMENT, L.P.unchanged · filed 14 Aug 202626,975,505$156.7M00.0%
BlackRock, Inc.added · filed 7 Aug 202619,202,461$111.6M+5,085,049+36.0%
GSK plcunchanged · filed 13 Aug 202618,245,691$106.0M00.0%
MAVERICK CAPITAL LTDadded · filed 14 Aug 202610,278,115$59.7M+116,716+1.1%
Driehaus Capital Management LLCadded · filed 14 Aug 20265,443,143$31.6M+12,122+0.2%
PRIMECAP MANAGEMENT COadded · filed 14 Aug 20265,354,622$31.1M+521,670+10.8%
683 Capital Management, LLCadded · filed 14 Aug 20264,950,000$28.8M+50,000+1.0%
FMR LLCreduced · filed 13 Aug 20264,922,477$28.6M-270,284−5.2%
STATE STREET CORPadded · filed 7 Aug 20264,839,317$28.1M+1,165,284+31.7%
READYSTATE ASSET MANAGEMENT LPnew · filed 14 Aug 20264,727,139$27.5M+4,727,139
31 Mar 2023 – 30 Jun 2026
66144222Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

Adrian Rawcliffe Company insiderDirector · last 5 Oct 20260 · 3
Aik Na Tan Company insiderDirector · last 5 Oct 20260 · 4
Christian O. Henry Company insiderDirector · last 5 Oct 20260 · 3
Gregory L. Verdine Company insiderDirector · last 5 Oct 20260 · 6
Heidi L. Wagner Company insiderDirector · last 5 Oct 20260 · 2
Ken Takanashi Company insiderDirector · last 5 Oct 20261 · 2
Mark Corrigan Company insiderDirector · last 5 Oct 20260 · 1
RA CAPITAL MANAGEMENT, L.P. Company insiderDirector, 10% owner · last 5 Oct 20268 · 0
Chris Francis Company insiderOfficer · last 26 Feb 20260 · 19
Chandra Vargeese Company insiderOfficer · last 9 Feb 20260 · 12
Kyle Moran Company insiderChief Financial Officer · last 9 Feb 20260 · 10
Paul Bolno Company insiderPresident and CEO · last 9 Feb 20260 · 22

Same industry

MRNA ModernaLeading+167%
ENTX Entera BioLeading+52%
XNCR XencorLeading+41%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Operating profit marginFY 2025 · to 31 Dec 2025-504%
Free cash flow marginFY 2025 · to 31 Dec 2025-440%
Return on capital employedFY 2025 · to 31 Dec 2025-39.6%
Research spendFY 2025 · to 31 Dec 2025428%
Share count trendFY 2025 · to 19 Feb 20260.3%
Cash and equivalentsFY 2025 · to 31 Dec 2025$602.1M
Free cash flowFY 2025 · to 31 Dec 2025−$188.2M

Analyst forecasts

No analyst forecasts yet.